酶替代疗法在CLN2相关的视网膜病变中
Claudia Priglinger1, Carolina Courage2, Esther M Maier3,4
1Department of Ophthalmology, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Klinische Monatsblatter fur Augenheilkunde
|March 24, 2025
概括
用复合人TPP1 (rhTPP1) 进行酶替代疗法,有望减缓CLN2疾病中的视网膜退化,维护视力和改善生活质量. 这种内治疗为等待基因疗法等先进治疗的患者提供了潜在的桥梁疗法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 眼科医生 眼科 眼科
背景情况:
- 神经神经状脂症 (巴顿病) 是一种罕见的遗传性神经退行性疾病.
- 由TPP1基因突变引起的CLN2疾病导致逐渐的视力丧失和神经衰退.
- 目前用于CLN2疾病的脑内静脉酶替代疗法 (ERT) 可以减缓精神运动衰退,但不能减缓视力损失.
研究的目的:
- 审查目前关于ERT对CLN2视网膜病变的知识.
- 评估内复合人TPP1 (rhTPP1) 在维护视觉功能的安全性和有效性.
- 讨论内ERT作为桥梁治疗的潜力.
主要方法:
- 审查关于ERT对CLN2疾病的现有文献.
- 对内rhTPP1.1.的一项同情使用研究的分析.
- 讨论正在进行和计划的临床试验.
主要成果:
- 内rhtPP1在犬模型和人类患者中证明了减少黄斑体积损失的安全性和有效性.
- 该疗法显著延缓视网膜退化,保持视觉功能.
- 对CLN2视网膜病变的ERT似乎是安全的,并改善了患者的生活质量.
结论:
- 静脉内膜rhTPP1是一种安全有效的治疗CLN2视网膜病变.
- 这种疗法可以保持视觉功能,并提高受影响个体的生活质量.
- 在基因疗法等更明确的治疗方法出现之前,静脉内肠道ERT可能成为关键的桥梁疗法.
相关概念视频
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
420
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
420
01:30Continuous Renal Replacement Therapy
2.4K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.4K